Project Details
Description
A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB (MPDL3280A, ANTI PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN OR CISPLATIN PEMETREXED COMPARED WITH CARBOPLATIN OR CISPLATIN PEMETREXED IN PATIENTS WHO ARE CHEMOTHERAPY-NAIVE AND
| Status | Finished |
|---|---|
| Effective start/end date | 2/1/16 → 12/31/20 |
Funding
- GENENTECH, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.